SCHEMBL25944246

SCHEMBL25944246

c1ccc(-c2cccc(-c3ccc(-c4nc(-c5ccc6c(c5)sc5ccccc56)nc(-c5cccc6sc7ccccc7c56)n4)cc3)c2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.36
MAPT P10636 3/20 0.36
HPGD P15428 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
RAB9A P51151 1/20 0.36
LIMK1 P53667 1/20 0.36
PIK3CA P42336 1/20 0.35
PI4KA P42356 1/20 0.35
PI4KB Q9UBF8 1/20 0.35
F9 P00740 1/20 0.35
ALOX5 P09917 1/20 0.35
PIM3 Q86V86 1/20 0.35
GPR3 P46089 1/20 0.34
ADORA2A P29274 2/20 0.33
ADORA1 P30542 2/20 0.33
MCL1 Q07820 1/20 0.33
TSHR P16473 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
ADORA3 P0DMS8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25944419 0.99 ALDH1A1 (0.37) ALDH1A1MAPTHPGDSMN1; SMN2RAB9A
SCHEMBL26080442 0.99 ALDH1A1 (0.37) ALDH1A1MAPTHPGDSMN1; SMN2RAB9A
SCHEMBL22329342 0.99 ALDH1A1 (0.37) ALDH1A1MAPTHPGDSMN1; SMN2RAB9A
SCHEMBL21149140 0.97 ALDH1A1 (0.38) ALDH1A1MAPTHPGDSMN1; SMN2RAB9A
SCHEMBL26080609 0.96 F9 (0.37) ALDH1A1MAPTHPGDSMN1; SMN2RAB9A
SCHEMBL22329566 0.96 LIMK1 (0.38) ALDH1A1MAPTHPGDLIMK1PIK3CA
SCHEMBL25645881 0.96 LIMK1 (0.38) ALDH1A1MAPTHPGDLIMK1PIK3CA
SCHEMBL22329289 0.96 LIMK1 (0.38) ALDH1A1MAPTHPGDLIMK1PIK3CA
SCHEMBL25644274 0.96 ALDH1A1 (0.39) ALDH1A1MAPTHPGDSMN1; SMN2RAB9A
SCHEMBL19802138 0.95 PIM3 (0.39) ALDH1A1MAPTHPGDSMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-10-05 US disclosed
US-20230312538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-10-05 US disclosed
EP-4212526-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT Materials Co., Ltd. (KR) 2023-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME CRY1, CYP1A1, CYP1B1 ALDH1A1 18/4885MAPT 1271/4885HPGD 791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.